Skip to main content
. 2023 Sep 9;6(4):240–252. doi: 10.1093/abt/tbad020

Figure 4.

Figure 4

In vivo efficacy of IMM47 anti-tumor activities in transplanted mouse models. (A) In vivo efficacy assay: hSiglec-10 Tg C57BL/6 mice congenitally transplanted with MC38-hCD24. IMM47 showed strong anti-tumor activity on the homologous model of MC38-hCD24 cells inoculated into hSiglec-10 transgenic C57BL/6 mice, and the tumor in the treatment group was eliminated. (B) The mice in the treatment group were inoculated with tumor cells again, but the tumor cells could not form tumors, suggesting that a memory immune response was formed after treatment with IMM47. (C) In vivo efficacy in C57BL/6 mice congenitally transplanted with MC38-hCD24: IMM47 and IMM47C (chimeric Ab) showed strong anti-tumor activity in C57BL/6 wild-type mice inoculated with the MC38-hCD24 cell homologous model. There was no significant difference between the two groups. (D) The tumor cells CD24 expression were measured after IMM47 treatment by FACS. The tumor was stripped at the end of the experiment, and the cell suspension was prepared to detect the expression of CD24 on the surface of tumor cells. The CD24 expression on tumor cells in the treatment group mice was significantly downregulated and tumor growth was inhibited. IMM47 not only exhibited potent Fc-dependent effector functions to attack on tumor cells but also inhibited the Siglec-10/CD24 signal by downregulating CD24 expression of tumor cell.